{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:41:51Z","timestamp":1790516511358,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T00:00:00Z","timestamp":1525305600000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NIH\/NCI","award":["P50CA186781"],"award-info":[{"award-number":["P50CA186781"]}]},{"name":"NIH\/NCI","award":["R01CA175795"],"award-info":[{"award-number":["R01CA175795"]}]},{"name":"Mayo Clinic Comprehensive Cancer Center","award":["P30CA015083"],"award-info":[{"award-number":["P30CA015083"]}]},{"name":"Al and Mary Agnes McQuinn Foundation"},{"DOI":"10.13039\/100009769","name":"David F. and Margaret T. Grohne Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ymthe.2017.03.026","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T02:16:44Z","timestamp":1491531404000},"page":"1107-1116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"title":["Oncolytic Virotherapy: A Contest between Apples and Oranges"],"prefix":"10.1016","volume":"25","author":[{"given":"Stephen J.","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kah-Whye","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2017.03.026_bib1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/bjc.2015.481","article-title":"Oncolytic viruses: finally delivering","volume":"114","author":"Seymour","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2017.03.026_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2017.03.026_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma","volume":"18","author":"Bommareddy","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib5","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib6","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"Suppl.; abstr. 9568","key":"10.1016\/j.ymthe.2017.03.026_bib7","article-title":"Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene lapherparevec (T-VEC) and pembrolizuman (pembro) for unresectable stage IIIB-IV melanoma","volume":"34","author":"Long","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib9","doi-asserted-by":"crossref","DOI":"10.2217\/fvl-2016-0129","article-title":"Designing and building oncolytic viruses","author":"Maroun","year":"2017","journal-title":"Future Virol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00109-016-1453-9","article-title":"Oncolytic viruses\u2014immunotherapeutics on the rise","volume":"94","author":"Keller","year":"2016","journal-title":"J.\u00a0Mol. Med. (Berl.)"},{"key":"10.1016\/j.ymthe.2017.03.026_bib11","article-title":"Oncolytic viruses in cancer treatment: a review","author":"Lawler","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib12","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1126\/science.1851332","article-title":"Experimental therapy of human glioma by means of a genetically engineered virus mutant","volume":"252","author":"Martuza","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2017.03.026_bib13","doi-asserted-by":"crossref","first-page":"e1005449","DOI":"10.1371\/journal.ppat.1005449","article-title":"The herpes simplex virus neurovirulence factor \u03b334.5: revealing virus-host interactions","volume":"12","author":"Wilcox","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2017.03.026_bib14","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.2174\/138920112800958814","article-title":"Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress","volume":"13","author":"Kaur","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib15","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib16","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma","volume":"17","author":"Kaufman","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib17","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2017.03.026_bib18","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/gt.2010.66","article-title":"Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection","volume":"17","author":"Hong","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib19","first-page":"2727","article-title":"Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms","volume":"9","author":"Nakamori","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2017.03.026_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/978-1-59745-561-9_29","article-title":"Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor control","volume":"542","author":"Simpson","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib21","doi-asserted-by":"crossref","first-page":"10153","DOI":"10.1128\/JVI.01133-08","article-title":"Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2","volume":"82","author":"Menotti","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.coviro.2016.08.007","article-title":"Retargeting of herpes simplex virus (HSV) vectors","volume":"21","author":"Goins","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib23","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1158\/1078-0432.CCR-09-0051","article-title":"MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells","volume":"15","author":"Lee","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2017.03.026_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/mt.2014.177","article-title":"Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV","volume":"23","author":"Mazzacurati","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib25","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1158\/0008-5472.CAN-04-3227","article-title":"An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor","volume":"65","author":"Kambara","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.03.026_bib26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/mt.2011.208","article-title":"Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and \u201cVstat120\u201d-expressing oncolytic virus","volume":"20","author":"Yoo","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib27","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-017-0516-0","article-title":"Oncolytic virotherapy for the treatment of malignant glioma","author":"Foreman","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymthe.2017.03.026_bib28","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2217\/fvl.11.76","article-title":"Oncolytic poliovirus against malignant glioma","volume":"6","author":"Goetz","year":"2011","journal-title":"Future Virol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib29","doi-asserted-by":"crossref","first-page":"341ra75","DOI":"10.1126\/scitranslmed.aad9784","article-title":"Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma","volume":"8","author":"Cloughesy","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"Suppl. 3","key":"10.1016\/j.ymthe.2017.03.026_bib30","doi-asserted-by":"crossref","first-page":"iii39","DOI":"10.1093\/neuonc\/nou208.61","article-title":"First-in-human phase I clinical trial of oncolytic delta-24-RGD (DNX-2401) with biological endpoints: Implications for viro-immunotherapy","volume":"16","author":"Lang","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1471-2407-12-99","article-title":"Phase I\/IIa study of intratumoral\/intracerebral or intravenous\/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol","volume":"12","author":"Geletneky","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ymthe.2017.03.026_bib32","first-page":"1666","article-title":"[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]","volume":"23","author":"Xia","year":"2004","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.ymthe.2017.03.026_bib33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/156800907780058817","article-title":"Clinical trials with oncolytic adenovirus in China","volume":"7","author":"Yu","year":"2007","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ymthe.2017.03.026_bib34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2017.03.026_bib35","first-page":"149135","article-title":"Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections","volume":"2012","author":"Chentoufi","year":"2012","journal-title":"Clin. Dev. Immunol."},{"issue":"Suppl.; abstract 9543","key":"10.1016\/j.ymthe.2017.03.026_bib36","article-title":"Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma","volume":"34","author":"Andtbacka","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14712598.2016.1100162","article-title":"The use of the NIS reporter gene for optimizing oncolytic virotherapy","volume":"16","author":"Miller","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2017.03.026_bib38","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/343739","article-title":"Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review","volume":"186","author":"Smith","year":"2002","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2017.03.026_bib39","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1086\/340041","article-title":"Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994","volume":"185","author":"Xu","year":"2002","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2017.03.026_bib40","first-page":"327","article-title":"Pathogenesis of viral infection","volume":"Volume 1","author":"Virgin","year":"2007"},{"key":"10.1016\/j.ymthe.2017.03.026_bib41","first-page":"1551","article-title":"Measles virus","volume":"Volume 2","author":"Griffin","year":"2007"},{"key":"10.1016\/j.ymthe.2017.03.026_bib42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/rmv.480","article-title":"Convalescent whole blood, plasma and serum in the prophylaxis of measles: JAMA, 12 April, 1926; 1180-1187","volume":"15","author":"Zingher","year":"2005","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib43","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/1097-0142(194905)2:3<525::AID-CNCR2820020317>3.0.CO;2-O","article-title":"The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180","volume":"2","author":"Moore","year":"1949","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2017.03.026_bib44","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2012.70","article-title":"Curative one-shot systemic virotherapy in murine myeloma","volume":"26","author":"Naik","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2017.03.026_bib45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0304-3835(01)00617-6","article-title":"Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration","volume":"172","author":"Phuangsab","year":"2001","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2017.03.026_bib46","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1128\/JVI.02810-15","article-title":"MicroRNA-detargeted mengovirus for oncolytic virotherapy","volume":"90","author":"Ruiz","year":"2016","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib47","first-page":"1471","article-title":"Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21","volume":"26","author":"Au","year":"2005","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib48","first-page":"8751","article-title":"Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes","volume":"61","author":"McCart","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.03.026_bib49","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/noq148","article-title":"A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models","volume":"13","author":"Yu","year":"2011","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib50","doi-asserted-by":"crossref","first-page":"e73759","DOI":"10.1371\/journal.pone.0073759","article-title":"Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters","volume":"8","author":"Bailey","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2017.03.026_bib51","doi-asserted-by":"crossref","first-page":"14005","DOI":"10.1038\/mto.2014.5","article-title":"Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy","volume":"1","author":"Miller","year":"2014","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2017.03.026_bib52","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/mt.2011.26","article-title":"Targeting tumor vasculature with an oncolytic virus","volume":"19","author":"Breitbach","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib53","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/0008-5472.CAN-12-2687","article-title":"Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans","volume":"73","author":"Breitbach","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.03.026_bib54","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1089\/hum.2005.16.765","article-title":"Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma","volume":"16","author":"Benencia","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib55","doi-asserted-by":"crossref","first-page":"e1000820","DOI":"10.1371\/journal.ppat.1000820","article-title":"MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference","volume":"6","author":"Kelly","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2017.03.026_bib56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.mt.6300039","article-title":"Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity","volume":"15","author":"Power","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib57","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.exphem.2013.01.010","article-title":"Enhancing cytokine-induced killer cell therapy of multiple myeloma","volume":"41","author":"Liu","year":"2013","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib58","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1158\/1078-0432.CCR-09-1292","article-title":"Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model","volume":"15","author":"Mader","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2017.03.026_bib59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1479-5876-11-20","article-title":"Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer","volume":"11","author":"Mader","year":"2013","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.ymthe.2017.03.026_bib60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.coviro.2015.03.007","article-title":"MicroRNAs and oncolytic viruses","volume":"13","author":"Ruiz","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib61","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.tips.2007.05.005","article-title":"Viruses as anticancer drugs","volume":"28","author":"Russell","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2017.03.026_bib62","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.seminoncol.2005.09.007","article-title":"Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects","volume":"32","author":"Thorne","year":"2005","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib63","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.addr.2009.03.013","article-title":"Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis","volume":"61","author":"Dorer","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2017.03.026_bib64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/B978-0-12-398342-8.00002-1","article-title":"Chapter two--Adenovirus strategies for tissue-specific targeting","volume":"115","author":"Beatty","year":"2012","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.ymthe.2017.03.026_bib65","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1517\/14712598.4.10.1685","article-title":"Oncolytic measles viruses for cancer therapy","volume":"4","author":"Nakamura","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib66","doi-asserted-by":"crossref","first-page":"e1003836","DOI":"10.1371\/journal.ppat.1003836","article-title":"From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer","volume":"10","author":"Ilkow","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2017.03.026_bib67","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","article-title":"Remission of disseminated cancer after systemic oncolytic virotherapy","volume":"89","author":"Russell","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ymthe.2017.03.026_bib68","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/978-1-61779-095-9_14","article-title":"Manufacture of measles viruses","volume":"737","author":"Langfield","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib69","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Breitbach","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2017.03.026_bib70","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/nm.1776","article-title":"Engineering microRNA responsiveness to decrease virus pathogenicity","volume":"14","author":"Kelly","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2017.03.026_bib71","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0196-6553(82)90003-7","article-title":"The global eradication of smallpox","volume":"10","author":"Strassburg","year":"1982","journal-title":"Am. J. Infect. Control"},{"key":"10.1016\/j.ymthe.2017.03.026_bib72","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/tvjl.1998.0303","article-title":"Vesicular stomatitis","volume":"157","author":"Letchworth","year":"1999","journal-title":"Vet. J."},{"key":"10.1016\/j.ymthe.2017.03.026_bib73","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1006\/mthe.2000.0133","article-title":"Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model","volume":"2","author":"Lambright","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib74","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1158\/1078-0432.CCR-10-3266","article-title":"Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization","volume":"17","author":"Ilett","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2017.03.026_bib75","first-page":"183","article-title":"Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy","volume":"4","author":"Nakashima","year":"2015","journal-title":"Oncolytic Virother."},{"key":"10.1016\/j.ymthe.2017.03.026_bib76","doi-asserted-by":"crossref","first-page":"14981","DOI":"10.1073\/pnas.0803988105","article-title":"Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis","volume":"105","author":"Nguy\u00ean","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2017.03.026_bib77","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fonc.2014.00191","article-title":"Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses","volume":"4","author":"Forbes","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib78","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/mt.2010.67","article-title":"A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers","volume":"18","author":"Diallo","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib79","doi-asserted-by":"crossref","first-page":"26786","DOI":"10.1038\/srep26786","article-title":"First-in-class small molecule potentiators of cancer virotherapy","volume":"6","author":"Dornan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2017.03.026_bib80","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1517\/14712590903170653","article-title":"Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways","volume":"9","author":"Naik","year":"2009","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib81","doi-asserted-by":"crossref","first-page":"a015487","DOI":"10.1101\/cshperspect.a015487","article-title":"Immunosuppressive drug therapy","volume":"3","author":"Hartono","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ymthe.2017.03.026_bib82","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1128\/JVI.02127-08","article-title":"Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters","volume":"83","author":"Dhar","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib83","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-07-1510","article-title":"Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus","volume":"14","author":"Qiao","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2017.03.026_bib84","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/gt.2012.31","article-title":"Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses","volume":"20","author":"Peng","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib85","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/sj.clpt.6100409","article-title":"Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide","volume":"82","author":"Myers","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib86","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/annonc\/mdw534","article-title":"Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies","volume":"28","author":"Salama","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib87","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2017.03.026_bib88","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.vaccine.2016.05.073","article-title":"Personalized cancer vaccines: Targeting the cancer mutanome","volume":"35","author":"Zhang","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2017.03.026_bib89","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1158\/2326-6066.CIR-14-0124-T","article-title":"PolySia-specific retargeting of oncolytic viruses triggers tumor-specific immune responses and facilitates therapy of disseminated lung cancer","volume":"3","author":"Kloos","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2017.03.026_bib90","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood-2015-06-652503","article-title":"Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia","volume":"127","author":"Shen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.03.026_bib91","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdw379.04","article-title":"Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresectable melanoma","volume":"27","author":"Chesney","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2017.03.026_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2017.01.023","article-title":"Inhibitory receptors induced by VSV viroimmunotherapy are not necessarily targets for improving treatment efficacy","author":"Shim","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib93","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1158\/0008-5472.CAN-12-0600","article-title":"Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer","volume":"72","author":"Rommelfanger","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.03.026_bib94","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/hum.2010.216","article-title":"Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus","volume":"22","author":"Wongthida","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.026_bib95","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.cvsm.2007.08.003","article-title":"Comparative oncology today","volume":"37","author":"Paoloni","year":"2007","journal-title":"Vet. Clin. North Am. Small Anim. Pract."},{"key":"10.1016\/j.ymthe.2017.03.026_bib96","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.3390\/v6052122","article-title":"Oncolytic virotherapy of canine and feline cancer","volume":"6","author":"Gentschev","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2017.03.026_bib97","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1089\/humc.2013.165","article-title":"Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs","volume":"24","author":"LeBlanc","year":"2013","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2017.03.026_bib98","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/v8010003","article-title":"Newcastle disease virus: potential therapeutic application for human and canine lymphoma","volume":"8","author":"S\u00e1nchez","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2017.03.026_bib99","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4161\/bioe.22462","article-title":"Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy","volume":"4","author":"Gentschev","year":"2013","journal-title":"Bioengineered"},{"key":"10.1016\/j.ymthe.2017.03.026_bib100","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/mt.2014.7","article-title":"A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology","volume":"22","author":"Laborda","year":"2014","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617301259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617301259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:54:36Z","timestamp":1657673676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001617301259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1525001617301259"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.026","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic Virotherapy: A Contest between Apples and Oranges","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}